O	0	6	Breast
O	7	13	cancer
O	14	18	risk
O	19	25	status
O	26	36	influences
O	37	43	uptake
O	43	44	,
O	45	54	retention
O	55	58	and
O	59	67	efficacy
O	68	70	of
O	71	72	a
B-intervention	73	79	weight
I-intervention	80	84	loss
I-intervention	85	94	programme
O	95	102	amongst
O	103	109	breast
O	110	116	cancer
O	117	126	screening
O	127	136	attendees
O	136	137	:
O	138	141	two
O	142	152	randomised
O	153	163	controlled
O	164	175	feasibility
O	176	182	trials
O	182	183	.

O	184	190	Excess
O	191	195	body
O	196	202	weight
O	203	206	and
O	207	210	sub
O	210	211	-
O	211	218	optimal
O	219	228	lifestyle
O	229	232	are
O	233	243	modifiable
O	244	250	causes
O	251	253	of
O	254	260	breast
O	261	267	cancer
O	268	271	and
O	272	277	other
O	278	286	diseases
O	286	287	.

O	288	293	There
O	294	296	is
O	297	303	little
O	304	312	evidence
O	313	317	that
O	318	327	behaviour
O	328	334	change
O	335	337	is
O	338	346	possible
O	347	353	within
O	354	363	screening
O	364	374	programmes
O	375	378	and
O	379	386	whether
O	387	391	this
O	392	394	is
O	395	405	influenced
O	406	408	by
O	409	414	prior
O	415	424	knowledge
O	425	427	of
O	428	435	disease
O	436	440	risk
O	440	441	.

O	442	444	We
O	445	455	determined
O	456	463	whether
O	464	470	breast
O	471	477	cancer
O	478	482	risk
O	483	493	influences
O	494	500	uptake
O	500	501	,
O	502	511	retention
O	512	515	and
O	516	524	efficacy
O	525	527	of
O	528	529	a
O	530	536	weight
O	537	544	control
O	545	554	programme
O	555	557	in
O	558	561	the
O	562	564	UK
O	565	573	National
O	574	580	Health
O	581	588	Service
O	589	595	Breast
O	596	605	Screening
O	606	615	Programme
O	615	616	,
O	617	620	and
O	621	628	whether
O	629	639	additional
O	640	654	cardiovascular
O	655	662	disease
O	663	666	and
O	667	671	type
O	672	673	2
O	674	682	diabetes
O	683	687	risk
O	688	699	information
O	700	708	improves
O	709	715	uptake
O	716	719	and
O	720	729	retention
O	730	737	further
O	737	738	.

B-eligibility	739	749	Overweight
I-eligibility	749	750	/
I-eligibility	750	755	obese
I-eligibility	756	761	women
O	762	764	in
O	765	768	the
B-location	769	771	UK
O	772	780	National
O	781	787	Health
O	788	795	Service
O	796	802	Breast
O	803	812	Screening
O	813	822	Programme
B-eligibility	823	833	identified
I-eligibility	834	836	at
I-eligibility	837	841	high
I-eligibility	841	842	,
I-eligibility	843	853	moderately
I-eligibility	854	863	increased
I-eligibility	863	864	,
I-eligibility	865	872	average
I-eligibility	873	876	and
I-eligibility	877	880	low
I-eligibility	880	881	-
I-eligibility	881	885	risk
I-eligibility	886	888	of
I-eligibility	889	895	breast
I-eligibility	896	902	cancer
O	903	907	were
O	908	918	randomised
O	919	921	to
O	922	929	receive
O	930	944	individualised
O	945	951	breast
O	952	958	cancer
O	959	963	risk
O	964	975	information
O	976	977	(
O	977	983	breast
O	984	990	cancer
O	991	1001	prevention
O	1002	1011	programme
O	1011	1012	)
O	1012	1013	,
O	1014	1016	or
O	1017	1031	individualised
O	1032	1038	breast
O	1039	1045	cancer
O	1045	1046	,
O	1047	1061	cardiovascular
O	1062	1069	disease
O	1070	1071	(
O	1071	1077	QRISK2
O	1077	1078	)
O	1079	1082	and
O	1083	1087	type
O	1088	1089	2
O	1090	1098	diabetes
O	1099	1100	(
O	1100	1109	QDiabetes
O	1109	1110	,
O	1111	1116	HbA1c
O	1116	1117	)
O	1118	1129	information
O	1130	1131	(
O	1131	1139	multiple
O	1140	1147	disease
O	1148	1158	prevention
O	1159	1168	programme
O	1168	1169	)
O	1169	1170	.

O	1171	1183	Personalised
O	1184	1190	breast
O	1191	1197	cancer
O	1198	1202	risk
O	1203	1211	feedback
O	1212	1215	was
O	1216	1221	given
O	1222	1228	before
O	1229	1242	randomisation
O	1243	1245	in
O	1246	1251	Study
O	1251	1252	-
O	1252	1253	1
O	1253	1254	,
O	1255	1258	and
O	1259	1264	after
O	1265	1278	randomisation
O	1279	1281	in
O	1282	1287	Study
O	1287	1288	-
O	1288	1289	2
O	1289	1290	.

O	1291	1302	Recruitment
O	1303	1306	was
O	1307	1308	9
O	1308	1309	%
O	1310	1311	(
B-total-participants	1311	1314	126
O	1314	1315	/
O	1315	1319	1356
O	1319	1320	)
O	1321	1323	in
O	1324	1329	Study
O	1329	1330	-
O	1330	1331	1
O	1332	1335	and
O	1336	1337	7
O	1337	1338	%
O	1339	1340	(
B-total-participants	1340	1342	52
O	1342	1343	/
O	1343	1346	738
O	1346	1347	)
O	1348	1350	in
O	1351	1356	Study
O	1356	1357	-
O	1357	1358	2
O	1358	1359	.

O	1360	1364	With
O	1365	1372	respect
O	1373	1375	to
B-outcome	1376	1382	breast
I-outcome	1383	1389	cancer
I-outcome	1390	1394	risk
O	1394	1395	,
O	1396	1400	odds
O	1401	1406	ratio
O	1407	1409	of
O	1410	1416	uptake
O	1417	1420	for
O	1421	1425	high
O	1425	1426	/
O	1426	1436	moderately
O	1437	1446	increased
O	1447	1449	vs
O	1450	1453	low
O	1454	1458	risk
O	1459	1464	women
O	1465	1468	was
O	1469	1470	1
O	1470	1471	.
O	1471	1473	99
O	1474	1475	(
O	1475	1477	95
O	1477	1478	%
O	1479	1481	CI
O	1482	1483	1
O	1483	1484	.
O	1484	1486	24
O	1486	1487	-
O	1487	1488	3
O	1488	1489	.
O	1489	1491	17
O	1491	1492	,
O	1493	1494	P
O	1495	1496	=
O	1497	1498	0
O	1498	1499	.
O	1499	1502	004
O	1502	1503	)
O	1504	1506	in
O	1507	1512	Study
O	1512	1513	-
O	1513	1514	1
O	1515	1518	and
O	1519	1520	3
O	1520	1521	.
O	1521	1523	58
O	1524	1525	(
O	1525	1527	95
O	1527	1528	%
O	1529	1531	CI
O	1532	1533	1
O	1533	1534	.
O	1534	1536	59
O	1536	1537	-
O	1537	1538	8
O	1538	1539	.
O	1539	1541	07
O	1541	1542	,
O	1543	1544	P
O	1545	1546	=
O	1547	1548	0
O	1548	1549	.
O	1549	1552	002
O	1552	1553	)
O	1554	1556	in
O	1557	1562	Study
O	1562	1563	-
O	1563	1564	2
O	1564	1565	.

B-outcome	1566	1570	Odds
I-outcome	1571	1576	ratio
I-outcome	1577	1579	of
I-outcome	1580	1589	retention
I-outcome	1590	1593	for
I-outcome	1594	1598	high
I-outcome	1598	1599	/
I-outcome	1599	1609	moderately
O	1610	1619	increased
O	1620	1621	-
O	1621	1625	risk
O	1626	1628	vs
O	1628	1629	.
O	1630	1633	low
O	1634	1638	risk
O	1639	1644	women
O	1645	1648	was
O	1649	1650	2
O	1650	1651	.
O	1651	1653	98
O	1654	1655	(
O	1655	1657	95
O	1657	1658	%
O	1659	1661	CI
O	1662	1663	1
O	1663	1664	.
O	1664	1666	05
O	1666	1667	-
O	1667	1668	8
O	1668	1669	.
O	1669	1671	47
O	1671	1672	,
O	1673	1674	P
O	1675	1676	=
O	1677	1678	0
O	1678	1679	.
O	1679	1682	041
O	1682	1683	)
O	1684	1686	in
O	1687	1692	Study
O	1692	1693	-
O	1693	1694	1
O	1695	1698	and
O	1699	1700	3
O	1700	1701	.
O	1701	1703	88
O	1704	1705	(
O	1705	1707	95
O	1707	1708	%
O	1709	1711	CI
O	1712	1713	1
O	1713	1714	.
O	1714	1716	07
O	1716	1717	-
O	1717	1719	14
O	1719	1720	.
O	1720	1722	04
O	1722	1723	,
O	1724	1725	P
O	1726	1727	=
O	1728	1729	0
O	1729	1730	.
O	1730	1733	039
O	1733	1734	)
O	1735	1737	in
O	1738	1743	Study
O	1743	1744	-
O	1744	1745	2
O	1745	1746	.

B-outcome	1747	1753	Weight
I-outcome	1754	1758	loss
O	1759	1761	of
O	1762	1763	â‰¥
O	1763	1764	5
O	1764	1765	%
O	1766	1768	at
O	1769	1771	12
O	1772	1778	months
O	1779	1782	was
O	1783	1791	achieved
O	1792	1794	by
B-iv-bin-percent	1795	1797	63
I-iv-bin-percent	1797	1798	%
O	1799	1803	high
O	1803	1804	/
O	1804	1812	moderate
O	1813	1815	vs
O	1815	1816	.
B-cv-bin-percent	1817	1819	43
I-cv-bin-percent	1819	1820	%
O	1821	1824	low
O	1824	1825	-
O	1825	1829	risk
O	1830	1835	women
O	1836	1838	in
O	1839	1844	Study
O	1844	1845	-
O	1845	1846	1
O	1847	1848	(
O	1848	1849	P
O	1850	1851	=
O	1852	1853	0
O	1853	1854	.
O	1854	1857	083
O	1857	1858	)
O	1859	1862	and
B-iv-bin-percent	1863	1865	39
I-iv-bin-percent	1865	1866	%
O	1867	1869	vs
O	1869	1870	.
B-cv-bin-percent	1871	1872	8
I-cv-bin-percent	1872	1873	%
O	1874	1876	in
O	1877	1882	Study
O	1882	1883	-
O	1883	1884	2
O	1885	1886	(
O	1886	1887	P
O	1888	1889	=
O	1890	1891	0
O	1891	1892	.
O	1892	1895	008
O	1895	1896	)
O	1896	1897	.

B-outcome	1898	1904	Uptake
O	1904	1905	,
B-outcome	1906	1915	retention
O	1916	1919	and
B-outcome	1920	1926	weight
I-outcome	1927	1931	loss
O	1932	1936	were
O	1937	1947	equivalent
O	1948	1950	in
O	1951	1955	both
O	1956	1959	the
O	1960	1966	breast
O	1967	1973	cancer
O	1974	1984	prevention
O	1985	1994	programme
O	1995	1998	and
O	1999	2002	the
O	2003	2011	multiple
O	2012	2019	disease
O	2020	2030	prevention
O	2031	2040	programme
O	2041	2043	in
O	2044	2048	both
O	2049	2056	studies
O	2056	2057	.

O	2058	2063	Women
O	2064	2067	who
O	2068	2071	are
O	2072	2080	informed
O	2081	2085	that
O	2086	2090	they
O	2091	2094	are
O	2095	2097	at
O	2098	2107	increased
O	2108	2114	breast
O	2115	2121	cancer
O	2122	2126	risk
O	2127	2131	were
O	2132	2145	significantly
O	2146	2150	more
O	2151	2157	likely
O	2158	2160	to
O	2161	2165	join
O	2166	2169	and
O	2170	2176	remain
O	2177	2179	in
O	2180	2183	the
O	2184	2194	programmes
O	2195	2198	and
O	2199	2211	consequently
O	2212	2216	lose
O	2217	2221	more
O	2222	2228	weight
O	2229	2235	across
O	2236	2240	both
O	2241	2248	studies
O	2248	2249	.

O	2250	2254	High
O	2255	2259	risk
O	2260	2265	women
O	2266	2269	are
O	2270	2274	more
O	2275	2281	likely
O	2282	2288	engage
O	2289	2291	in
O	2292	2293	a
O	2294	2302	lifetyle
O	2303	2313	prevention
O	2314	2323	programme
O	2324	2327	and
O	2328	2332	also
O	2333	2337	have
O	2338	2341	the
O	2342	2350	greatest
O	2351	2360	potential
O	2361	2368	benefit
O	2369	2372	fom
O	2373	2377	risk
O	2378	2387	reduction
O	2388	2398	strategies
O	2398	2399	.

O	2400	2414	ISRCTN91372184
O	2415	2425	Registered
O	2426	2428	28
O	2429	2438	September
O	2439	2443	2014
O	2443	2444	.
